A broad range of human leukemias carries RUNX1 and MLL genetic alterations. Despite such widespread involvements, the relationship between RUNX1 and MLL has never been appreciated. Recently, we showed that RUNX1 physically and functionally interacts with MLL, thereby regulating the epigenetic status of critical cis-regulatory elements for hematopoietic genes. This newly unveiled interaction between the two most prevalent leukemia genes has solved a long-standing conundrum: leukemia-associated RUNX1 N-terminal point mutants that exhibit no obvious functional abnormalities in classical assays for the assessment of transcriptional activities. These mutants turned out to be defective in MLL interaction and subsequent epigenetic modifications that can be examined by the histone-modification status of cis-regulatory elements in the target genes. RUNX1/MLL binding confirms the importance of RUNX1 function as an epigenetic regulator. Recent studies employing next-generation sequencing on human hematological malignancies identified a plethora of mutations in epigenetic regulator genes. These new findings would enhance our understanding on the mechanistic basis for leukemia development and may provide a novel direction for therapeutic applications. This review summarizes the current knowledge about the epigenetic regulation of normal and malignant hematopoiesis by RUNX1 and MLL. Leukemia (2013Leukemia ( ) 27, 1793Leukemia ( -1802 doi:10.1038/leu.2013 Keywords: RUNX1; AML1; MLL; epigenetic regulation INTRODUCTION RUNX1 and MLL are the two major genes that are frequently altered in B33 and 19% of human acute leukemias, respectively.
INTRODUCTION
RUNX1 and MLL are the two major genes that are frequently altered in B33 and 19% of human acute leukemias, respectively. [1] [2] [3] RUNX1-related leukemias account for about 32% of acute myeloid leukemia (AML), 4 ,5 23% of myelodysplastic syndrome (MDS) 6 and 37% of chronic myelomonocytic leukemia (CMML).
7 RUNX1 genetic alterations are also found in acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). 8, 9 Hence, RUNX1 abnormalities are now associated with a broad spectrum of leukemia. MLL alterations are also detected in both myeloid and lymphoid leukemias, although higher incidence of MLL abnormalities has been observed in ALL patients compared with AML patients. 10 Strikingly, 80% of the infant ALL is caused by MLL rearrangement. 11, 12 As RUNX1 or MLL genetic alterations are independently associated with distinct proportions of human leukemia, two genes have been thought to account for different subgroups of leukemia, and hence the relationship between RUNX1 and MLL was not well studied.
A TRANSCRIPTION FACTOR RUNX1 RUNX1 belongs to a small family of Runt-related heterodimeric transcription factor, polyomavirus enhancer-binding protein 2 (PEBP2)/core-binding factor (CBF) that is essential for the generation and maintenance of hematopoietic stem cells. [13] [14] [15] PEBP2/CBF consists of a DNA-binding a subunit, RUNX1 and a non-DNA-binding b subunit, PEBP2b/CBFb (henceforth b).
Heterodimerization of RUNX1 with its partner b subunit facilitates the DNA binding of RUNX1 in an allosteric manner at the regulatory regions of target genes. In addition, b heterodimerization also protects RUNX1 from ubiquitin-proteasomemediated degradation. 16 DNA binding and b heterodimerization of RUNX1 is mediated by an evolutionarily conserved 128 amino acid (aa) Runt domain (aa 50-177) located in its N-terminal region ( Figure 1 ). Several other functional domains that negatively or positively modulate RUNX1 transcriptional activity are also found in both N-and C-terminal moieties. 17 The RUNX1 C-terminal region contains transactivation and inhibition domains. 17, 18 A series of proteins, such as mSin3A, p300, MOZ, YAP and TAZ, are reported to interact with RUNX1 ( Figure 1 ). The interactions of those regulatory proteins facilitate post-translational modification and regulate lineage-specific gene expression in distinct cell types. 19 Phosphorylation of RUNX1 at C-terminal regions is shown to negatively regulate RUNX1 function in early hematopoiesis and T-cell differentiation. 20 In addition, a nuclear localization signal is found in the C-terminal border of the Runt domain. 18, 21 There is also a nuclear matrix-targeting signal present at the C-terminal portion of the RUNX1 protein to enhance nuclear matrix interaction for functional organization of the nucleus. 22 
GENETIC ALTERATIONS OF RUNX1 IN HUMAN LEUKEMIA
The importance of RUNX1 function in hematopoiesis is highlighted by its involvement in human leukemias. Prevalent types of RUNX1 genetic alterations in human leukemia are chromosomal rearrangement, copy number variation and point mutation.
A large proportion of RUNX1 genetic alterations found in leukemias are attributed to chromosomal translocations. 1, 23 To date, 39 types of RUNX1 chromosomal translocations have been reported in leukemia patients (http://atlasgeneticsoncology.org). RUNX1 was originally cloned from the breakpoint of chromosome 21 in t(8;21), a chromosomal translocation that accounts for B40% of patients with the AML M2 subtype. 24 Subsequently, a series of RUNX1 fusion proteins were identified: RUNX1-EVI1 produced by chromosomal translocation t(3;21) was reported to be associated with therapy-related AML, MDS and the blast phase of CML. 8, 25 The chromosomal translocation t(12;21) generating the TEL-RUNX1 fusion protein was observed in childhood ALL. 26 Notably, most RUNX1 fusion proteins retain their N-terminal and Runt domain but lack the C-terminal regulatory region. As such, the fusion proteins are defective in transcriptional regulation but are still capable of competing with the wild-type (WT) RUNX1 for DNA binding. Therefore, the dominant-negative effect against WT RUNX1 function by the RUNX1 fusion proteins is widely believed to be the common underlying mechanism for leukemogenesis throughout a variety of RUNX1-related chromosomal translocations.
RUNX1 copy number variations are also associated with malignant hematopoietic diseases. Down syndrome patients, carrying trisomy of chromosome 21 where RUNX1 is located, are more susceptible to AML and ALL. 27, 28 Trisomy 21 is also detected as a sole chromosomal abnormality in sporadic cases of AML. Furthermore, extra copies of RUNX1 (2-8 copies) due to the tandem repetition of a part of chromosome 21 including RUNX1 locus were also observed in ALL cells. 29 Conversely, deletions of 21q22.12 encompassing RUNX1 are implicated in both hereditary and sporadic leukemias. The germline deletion of RUNX1 alone is associated with familial platelet disorder with predisposition to AML (FPD/AML), whereas the deletion of relatively wider region encompassing RUNX1 is associated with syndromic thrombocytopenia accompanied by nonhematopoietic symptoms, such as mental retardation and heart malfunction. 30, 31 RUNX1 point mutations are predominantly reported in various myeloid malignancies. 5, [32] [33] [34] [35] Several tight relationships of RUNX1 point mutations to distinct subtypes of malignancy are documented: germline monoallelic RUNX1 mutations are observed in FPD/AML, 21, 36 whereas somatic monoallelic RUNX1 mutations are found most frequently in CMML 37 and AML with normal karyotype. 4 Somatic biallelic RUNX1 point mutations are tightly associated with the AML M0 subtype. 5, 38 Recently, RUNX1 point mutations were also found in immature T-ALL, including early T-cell precursor ALL. [39] [40] [41] A totally new mode of alteration, RUNX1 internal tandem duplication was discovered in FPD/AML due to the technological advances, such as next-generation sequencing. 42 The RUNX1 heterodimerization partner, CBFb, is also well documented to be mutated in human leukemias, largely through chromosome 16 inversion, inv(16) (p13q22), being observed in 12% of AML cases, particularly in almost all cases of AML-M4Eo subtype. 43 This inversion generates a fusion gene, CBFB-MYH11, encoding CBFb-smooth muscle myosin heavy chain fusion protein, which acts as a dominant repressor for RUNX1 function. 44 FUNCTIONAL CONSEQUENCES DUE TO RUNX1 POINT MUTATIONS Leukemia-associated RUNX1 point mutations are commonly clustered within the functionally important Runt domain, often resulting in the loss-of-RUNX1 protein function due to disruption of DNA binding and/or b heterodimerization capabilities. An electrophoretic mobility shift assay performed to examine the DNA binding and b heterodimerization of RUNX1 point mutants illustrated that about 50% of these RUNX1 Runt domain point mutants lacked DNA binding and/or b heterodimerization competency (Table 1, Figure 2 ). Mutant R174Q was totally defective in DNA binding, whereas b heterodimerization was completely lost in mutants, S67I, S67R and Q158H. Notably, these functional defects sustained by these particular point mutations are explained using the three-dimensional structure of the RUNX1 protein, wherein aa R174 and S67/Q158 are located within the loop or b-sheet responsible for direct interactions with DNA or b-subunit, respectively. 45 A mutant L117P was partially defective in DNA binding, as the band shifted by RUNX1 alone showed a smear pattern. In addition, perturbation of both DNA binding and b heterodimerization was observed in mutant A107P, in which band shifts by RUNX1 and RUNX1/b complex were both incomplete.
SPOTLIGHT
The nuclear localization mediated by nuclear localization signal located around the C-terminal end of Runt domain 18, 21 is important for full functionality of RUNX1 as a transcription factor. To determine the nuclear localization, RUNX1 point mutants were expressed in NIH3T3 cells and their subcellular localization was visualized by immunofluorescent staining with anti-RUNX1 antibody. WT RUNX1 protein was exclusively localized in the nucleus, and most of the RUNX1 point mutants we studied also exhibited distinct nuclear localization, with the exception of three Runt domain mutants (I150T, P156A and R174Q) and one C-terminal mutant (Y260X) ( Figure 3 ). All cells expressing the R174Q mutant exhibited RUNX1 staining in both the cytoplasm and the nucleus. On the other hand, we observed either distinct cytoplasmic or nuclear RUNX1 localization in cells expressing I150T or P156A mutant proteins. Mutant Y260X showed predominant cytoplasmic localization. Hence, mutants I150T, P156A, R174Q and Y260X were classified as nuclear localization-defective mutants (Table 1 ). Besides the above-mentioned nuclear localization signal, other multiple aa residues and domains are also involved in the nuclear localization. 18, 33, 46 The mutants that exhibited cytoplasmic localization are considered to contain defects in such additional domains. The cytoplasmic localization patterns in I150T, P156Q and Y260X seem to be intriguing, although these could be artifacts owing to the overexpression of RUNX1 mutant proteins. Recent studies showed that some abnormally misfolded proteins are preferentially accumulated in the endoplasmic reticulum, thereby causing endoplasmic reticulum-stress-associated human diseases including leukemia. 47 Therefore, precise investigation on the cytoplasmic localization of RUNX1 mutant proteins might provide further insights into pathogenic mechanisms.
Luciferase reporter assays performed revealed that most of the Runt-domain point mutants studied possessed reduced transcriptional activity in comparison to the WT RUNX1 ( Figure 4 ). Consistent with previous reports, the DNA-binding mutant R174Q, which failed to localize to the nucleus faithfully, showed a complete lack of transcriptional activity. A partially defective DNA-binding mutant, L117P, also demonstrated nearly complete abrogation in transcriptional activity. Severe reduction in transcriptional activity was also found in mutant A107P, in which DNA binding and b heterodimerization abilities were both partially disrupted. As expected, the mutants S67I, S67R and Q158H, all of which are completely defective in b heterodimerization, demonstrated reduced transcriptional activity. Consistent with a significant proportion of cells showing cytoplasmic localization of RUNX1 protein (Figure 3 ), a significant reduction in transcriptional activity was observed in both I150T and P156A mutants. Decrease in transcriptional activity was shown in Y260X, which is defective in nuclear localization. Unexpectedly, W79C and I166T mutants showed reduced transcriptional activity, although no defects were observed in DNA binding, b heterodimerization or nuclear localization.
Besides the above listed functional abnormalities, changes in RUNX1 protein stability might affect the RUNX1 transcriptional activity. The anaphase-promoting complex (APC), a mitosisregulating E3 ubiquitin ligase complex, was reported to modulate the protein amount of RUNX1 in cells cultured in vitro. 48, 49 The APC-activator protein Cdh1, but not Cdc20, was found to directly ubiquitylate RUNX1. To study whether RUNX1 point mutants affect their protein stability, in vitro ubiquitylation assay was conducted by using APC-Cdh1 ( Figure 5 ). Ubiquitylation rates of majority of the RUNX1 point mutants were comparable to that of the WT protein. However, mutants L117P and I150T showed reduction in ubiquitylation rate quantified by Typhoon Trio (Amersham Biosciences, Sunnyvale, CA, USA) (data not shown). Reduction of RUNX1 ubiquitylation rate is expected to potentially result in the reduction of protein degradation rate, thereby causing accumulation of the RUNX1 protein. Excess of RUNX1 mutant proteins may 
Functional consequences for the indicated mutants are shown: À , no or very weak; ± , weak; þ , normal; N, nucleus; C, cytoplasm; N.A., not available. proteins, which showed absolute impairment in transcriptional activity but still retained b heterodimerization and partial DNA binding, might compete with WT RUNX1, leading to a reduction in RUNX1-mediated transcriptional activity in the cells. Hence, protein degradation efficiency is also considered to be a key mechanism for RUNX1-mediated transcriptional activity and pathogenesis.
It is of note that although majority of the mutations are defective in DNA binding, b heterodimerization, nuclear Figure 3 . Subcellular localization of RUNX1 point mutants. Subcellular localization of RUNX1 mutants in NIH3T3 cells was examined by labeling RUNX proteins with rabbit anti-AML1 antibody (active motif), followed by Alexa Fluor 488-conjugated anti-rabbit secondary antibody (green). Nuclei were counterstained with 4,6-diamidino-2-phenylindole (DAPI) (blue). Half of the total transfected cells with I150T or P156A mutant proteins showed cytoplasmic localization, whereas the remaining half of the transfected cells revealed the nuclear pattern. WT, wild type. 

AN EPIGENETIC REGULATOR MLL
MLL is a histone methyltransferase that belongs to the Trithoraxgroup protein family, 50 and functions as a transcriptional activator, regulating gene expression during early development and hematopoiesis. MLL is also known as MLL1 and there are four other distinct MLL family genes, MLL2-MLL5. MLL works as a protein complex to modulate chromatin modification via methylation, acetylation and nucleosome remodeling. MLL is cleaved into N-terminal (MLL N ) and C-terminal (MLL C ) fragments by aspartic protease, namely taspase ( Figure 6) . 51 MLL N has a role in DNA binding and recognition. Menin is recruited by MLL N to form an interaction domain for LEDGF and contacts chromatin via a PWWP domain. 52 MLL N also includes an AT-hooks domain, which preferentially recognizes distorted DNA. Another functional domain in the N-terminal is a CxxC domain that discriminates the methylation status of DNA. 53 Four plant homeodomains (PHD) and one Bromo domain, responsible for protein-protein interaction and recognition of modified histone marks, are located around the center of MLL N . MLL C , on the other hand, has a role in chromatin remodeling for efficient transcription by modulating the efficiency of histone methylation and acetylation, through a SET domain, which holds histone H3K4 methyltransferase activity, and is responsible for interacting with at least four important proteins, MOF, WDR5, ASH2L and RBBP5. 54, 55 Transcription factors, such as p53 and b-catenin, are shown to recruit MLL complex to initiate transcription, 54, 56 and specific genes, such as the HOX genes, are highly dependent on the MLL complex for chromatin modification during transcription. 57, 58 Polymerase-associated factor complex (PAFc), HCF1/2, CYP33, CBP/p300, INI1 and DPY30 are also shown to interact with MLL. 59 All such interacting molecules are summarized in Figure 6 .
GENETIC ALTERATIONS OF MLL IN HUMAN LEUKEMIA
The deregulation of MLL by chromosomal translocation is frequently observed in both AML and ALL. Around 70% of MLL genetic alterations arise from chromosomal translocation. The causative factors of MLL chromosomal translocation are either spontaneous or therapy-related. Cancer patients treated with topoisomerase II inhibitor, such as etoposide, show high occurrence of MLL chromosomal translocation. 60, 61 More than 70 types of partner genes have been found to generate fusion proteins by chromosomal translocations with MLL. 59 The common MLL fusion partners are AF4, ENL, AF9, AF6, ELL and AF10. 62 The most prevalent MLL-AF4 is associated with infant pro-B ALL, 63, 64 whereas the MLL-ENL fusion protein is observed in both AML and ALL patients. Chromosomal translocations t(9;11) and t(6;11), generating MLL-AF9 and MLL-AF6, respectively, are mainly found in AML patients. MLL fusion proteins share some common features: most of them retain MLL N-terminal region and lack C-terminal moiety containing the SET domain, which was reported to be responsible for H3K4 methylation in the promoter regions of HOX genes ( Figure 6 ). 58 HOX genes have a key role in the regulation of hematopoietic development and aberrant HOX expression is known to be associated with leukemogenesis. [65] [66] [67] Inappropriate HOX gene expression is frequently correlated with MLL fusion protein in leukemia. 68, 69 In fact, upregulation of HOXA5, HOXA7 and HOXA9 were observed in MLL-related human leukemias. 70, 71 As such, deregulation of HOX genes due to MLL fusion protein appears to be one of the underlying mechanisms for MLL-related leukemogenesis.
Besides higher occurrence of the MLL fusion protein in human leukemia, MLL-PTD, which generates an in-frame repeat within the MLL N-terminal region (Figure 6 ), was also observed in 2.7% of myelodysplastic syndrome and 6.4% of AML patients, 3, [72] [73] [74] [75] [76] particularly in adult cytogenetically normal AML patients. 3, 76, 77 AML characterized by MLL-PTD is likely molecularly different from leukemias carrying MLL-translocation mutants, as deregulation of HOX genes were not observed. 69 Interestingly, RUNX1 point mutations and MLL-PTD were simultaneously found in the same AML patients, constituting a distinct clinical entity with unfavorable prognosis. 2, 78 We recently reported that the mice carrying MLL-PTD exhibit abnormal hematopoiesis with enhanced hematopoietic stem cell self-renewal, lineage bias and blockages in myeloid differentiation when stressed.
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RUNX1 MEETS MLL
Besides its crucial role as a transcription factor, RUNX1 is also documented to mediate epigenetic regulation in order to facilitate or inhibit multiple regulatory regions in the target genes. [80] [81] [82] [83] As RUNX1 itself does not possess any epigenetics-related enzymatic SPOTLIGHT Figure 5 . In vitro ubiquitylation assay of RUNX1 mutants. Ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and APCactivator (Cdh1) were expressed and purified from bacteria or baculovirus expression system. Anaphase-promoting complex (APC) was immunoprecipitated from Xenopus interphase extracts by anti-Cdc27, one of the APC subunits. After the APC activation by Cdh1, E1, E2 and in vitro-synthesized S35-methionine-labeled RUNX1 mutant protein were reacted in the presence of ATP. Phosphoimager was used to take images. Bands showing decreased intensities in L117P and I150T are highlighted by vertical lines.
activities, the interaction of RUNX1 with other epigenetic regulators is expected to underlie RUNX1-associated epigenetic regulation. Indeed, RUNX1 has been shown to interact with histone acetyl transferases (HAT), such as coactivators CBP, p300 and MOZ, 80, 81 and components of the histone deacetylase (HDAC) complex, such as Groucho/TLE and mSin3A. 84, 85 The interaction of RUNX1 with HAT acetylates chromatin-associated histones, which change the chromatin conformation and activate transcriptional activities. In contrast, HDACs act as repressors for gene expression by deacetylating nucleosomal core histone tails, which lead to tight chromatin conformation. RUNX1 also interact with distinct types of histone methyltransferases, such as SUV39H1 86 and PRMT6. 83 The binding of SUV39H1 followed by RUNX1 methylation in the N-terminal-negative regulatory region revokes RUNX1 function.
86 RUNX1 and PRMT6 interaction was reported to enhance H3R2 dimethylation, which inhibits transcriptional activity of RUNX1. 71 The dissociation of RUNX1 and PRMT6 interaction conversely promotes the interaction between RUNX1 and WDR5, which is a key component of the MLL complex, thereby initiating the expression of a subset of genes to induce differentiation of hematopoietic cells.
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RUNX1 and MLL proteins are both transcriptional regulators involved in epigenetic changes to govern proper hematopoiesis. MLL-PTD and RUNX1 mutations were observed simultaneously in a subtype of AML patients. 78 Therefore, it is anticipated that interaction between RUNX1 and MLL may exist in the regulation of multiple hematopoietic genes. [87] [88] [89] [90] Indeed, we have recently demonstrated that RUNX1 physically and functionally interacts with MLL. 91 The RUNX1 N-terminal region was found to directly bind to the MLL C-terminal region (Figure 7) . Immunoprecipitation assay showed that the elimination of RUNX1 aa 1-106 completely abolished MLL interaction, while this interaction gradually diminished after the elimination of RUNX1 aa 25 onwards. Therefore, RUNX1 aa 25-106 is considered to constitute a domain for MLL interaction, although aa 25-50 contributed to the interaction to a lesser extent (dotted line in Figure 7 ). On the other hand, MLL C-terminal region aa 2720-3969 was sufficient for RUNX1 binding, indicating that MLL aa 2720-3969 region appears to be the RUNX1 interaction domain. 91 It is known that two distinct RUNX1 promoters generate two different N-terminal ends of RUNX1 proteins starting with MAS or MRIP, full length of which are RUNX1c or RUNX1b, respectively. These two isoforms share the common aa sequences from position 6 onwards in RUNX1b and aa 33 onwards in RUNX1c. Therefore, MLL-binding affinities with the two RUNX1 N-terminal variants are likely to be comparable, as the differences are located outside the MLL-binding domain (aa .
Notably, the interaction between MLL and RUNX1 was found to be responsible for H3K4 tri-methylation in the upstream regulatory element (URE) and promoter regions of the PU.1 (SPI-1) gene, which is an ETS family member essential for the hematopoietic stem cell maintenance and development of macrophages and B cells. 91 Pu.1 is reported to be a major downstream target of Runx1 in adult mouse hematopoiesis. 92 Three and two RUNX-binding sites were identified at the PU.1 URE and promoter regions, respectively. The binding of RUNX1 at PU.1 URE positively and negatively regulates PU.1 expression in a cell context-dependent manner. Knockdown and rescue assays of MLL or RUNX1 were performed independently by using the early myeloid murine progenitor cell line 416B. Knockdown of MLL or RUNX1 showed less H3K4 tri-methylation, whereas reintroduction of MLL or RUNX1 restored H3K4 tri-methylation to normal levels, indicating that both genes are important to mediate H3K4 tri-methylation in the PU.1 URE and promoter regions. 91 suggesting that defective epigenetic regulation occurred probably due to the failure of MLL recruitment to the chromatin by RUNX1 N-terminal point mutants. This epigenetic deregulation is considered to be a basis for leukemogenesis in RUNX1 N-terminal mutants. We classify those RUNX1 N-terminal point mutants, which carry a defect in MLL binding, as 'MLL-binding-defective type' (Table 1) .
Our current proposed model for RUNX1-MLL-mediated epigenetic regulation at the regulatory regions of target genes, such as PU.1, is depicted in Figure 8 . Under normal conditions, RUNX1 first binds to the PU.1 URE region and recruits the MLL complex to open up part of the compact chromatin structure. Subsequently, RUNX1 binds to the partially relaxed PU.1 promoter region and recruits the MLL complex to further distort compact DNA structure. The relaxed form of PU.1 promoter region allows for the assembly of other transcriptional cofactors and initiates transcription of the PU.1 gene. On the other hand, RUNX1 N-terminal point mutants, which are defective in binding to MLL, fail to recruit the MLL complex to the targeted chromatin region, hence resulting in the continuation of silent mode for transcription.
MLL fusion proteins, lacking RUNX1-interacting C-terminal moiety, are considered to be defective in RUNX1 binding, leading to subsequent epigenetic deregulation. It is therefore plausible that the defective interaction between RUNX1 and MLL may be one of the underlying mechanisms for the prevalent MLL fusion-associated leukemias as well.
FUTURE PERSPECTIVES
Given that RUNX1 is shown to be involved in epigenetic regulation, classical transcriptional assays are apparently insufficient to examine a molecular basis for leukemogenesis caused by RUNX1 malfunction. Many RUNX1 N-terminal mutants discovered in patient samples have never been characterized due to the lack of methods to assess the epigenetic regulation by RUNX1. Our recent study clearly proves that cis-regulatory elements validated in vivo, such as PU.1 URE, serve as an experimental platform to examine epigenetic controls. A newly identified RUNX1 intronic enhancer, which is specifically active in long-term hematopoietic stem cells, 93 may also serve as another useful platform to assess epigenetic functions.
RUNX1 Runt domain and C-terminal region are shown to interact with many epigenetic modifiers, such as Bmi1, p300 and MOZ (Figure 1 ). Recent studies reported that epigenetic regulators, such as TET2, IDH1/2, EZH2, ASXL1 and DNMT3A, are frequently mutated in myeloid malignancies. 94 Currently unclassified RUNX1 mutants (class 4 mutants in Table 1 ) may be defective in interacting with these epigenetic factors, although it remains to be proven whether these leukemia-associated epigenetic regulators interact with RUNX1. RUNX1 mutations were recently observed in various solid tumors, such as esophagus and breast cancers besides hematological malignancies. 95 Alterations in MLL family genes were also reported in solid tumors. Hence, the usage of RUNX1-MLL epigenetics-related axis could be more widespread than previously thought. These new findings greatly enhance our understanding of the molecular mechanisms involved in cancer development and may provide a novel direction for future therapeutic applications.
SPOTLIGHT
